Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
16 Glaucoma Trials near New York, NY
Power is an online platform that helps thousands of Glaucoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Nicotinamide + Pyruvate for Open-Angle Glaucoma
New York, New YorkThe objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma.
A total of up to 188 participants will be enrolled and randomized 1:1 to receive N\&P or placebo for 87 weeks (20 months). Participants will be followed for a total of 91 weeks (21 months).
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:35 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Cataract, Dementia, Neurological Disease, Others
Must Be Taking:Glaucoma Medications
250 Participants Needed
Electrical Stimulation for Glaucoma
New York, New YorkThis trial is testing if using a home device that sends small electrical pulses to the eyes can help treat open-angle glaucoma. This condition causes eye nerves to die off quickly, and the study aims to see if this new method is safe and effective.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Ocular Herpes Zoster, Retinopathy, Uveitis, Pacemaker, Others
45 Participants Needed
System-Level Intervention for Visual Impairment
New York, New YorkOur team of community-based vision researchers has designed the Columbia University Multi-Level Intervention and Community-Engaged Research to Advance Vision Health (NEI-CER) to provide eye health screenings directly in Upper Manhattan communities, in familiar and accessible settings, to overcome multi-level social determinants of health (SDOH) which contribute to eye and vision health disparities. The proposed innovative, 2:1 cluster-randomized clinical trial, will recruit adults age 40 and older of diverse race/ethnicity (primarily African American and Hispanic/Latino) in Upper Manhattan with high rates of inadequate eye care. A total of 10 community health settings in Upper Manhattan, comprised of primary care offices, senior centers, and community organizations, confirms access to 17,000 individuals living at or below the NYC.gov poverty measure. This study will conduct ocular tests (visual acuity, intraocular pressure, fundus images) during screenings. To ensure that all participants receive the basic level of service, all participants who fail the eye health screening will be seen the same day by a study optometrist and eyeglasses will be provided at no charge. Educational workshops and a Community and Patient Advisory Board will support recruitment. System-Level Intervention Arm participants will receive ongoing support with scheduling eye exams and transportation by trained Community Engagement Coordinators. All participants will be followed prospectively for 2 years. The study is guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. An economic analysis will be conducted to evaluate the costs and benefits of the proposed multi-level Eye Health Screening Intervention. This will include calculating the cost per case of eye disease detected (such as glaucoma, cataracts, and retinal conditions) and assess the cost-effectiveness of the System-Level Intervention in comparison to Usual Care.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:40+
Sex:All
5840 Participants Needed
Patient Navigator Intervention for Vision Impairment or Blindness
New York, New YorkDr. Lisa A. Hark (PI and Study Chair) and an interdisciplinary team have designed the New York City Eye Study (NYCES) to promote eye and vision health by conducting eye health screenings in adults age 21+ (PAR-23-009/NOT-EY-22-004).
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:21+
Sex:All
10000 Participants Needed
MINIject™ Implant for Glaucoma
New York, New YorkThis trial is testing a small device called the MINIject™ implant, which is designed to help lower eye pressure in people with primary open-angle glaucoma. The device works by making it easier for fluid to drain from the eye, reducing pressure and potentially preventing vision loss.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:46+
Sex:All
Key Eligibility Criteria
Disqualifiers:Angle Closure Glaucoma, Degenerative Visual Disorders, Others
975 Participants Needed
XEN45 Gel Stent for Open-Angle Glaucoma
New York, New YorkGlaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach. Adverse events and intraocular pressure will be assessed.
XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is being studied in this study. Approximately 65 participants aged 45 years or older with open-angle glaucoma will be enrolled in this study at approximately 22 sites in the United States.
All participants will receive XEN45 implanted using the ab externo approach on Day 1 and will be followed for 12 months.
Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+
Sex:All
Key Eligibility Criteria
Disqualifiers:Unhealthy Conjunctiva, Excessive Bleeding, Others
65 Participants Needed
Long-term Safety and Efficacy of Bimatoprost SR for Glaucoma
New York, New YorkThis study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:18+
Sex:All
600 Participants Needed
AGN-193408 SR for Glaucoma
Newark, New JerseyThis trial is testing a new medication called AGN-193408 SR to see if it can safely lower eye pressure in people with open-angle glaucoma or ocular hypertension.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Ocular Trauma, Herpetic Ocular Diseases, Others
Must Not Be Taking:Corticosteroids
96 Participants Needed
Vision Screening + Patient Navigation for Eye Diseases
New York, New YorkThe investigators are conducting a 5-year prospective, 2:1 cluster-randomized controlled trial, funded by the Centers for Disease Control (CDC), which provides vision screenings to underserved New York City residents living in affordable housing buildings in Harlem and Washington Heights.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:40+
Sex:All
749 Participants Needed
Selective Laser Trabeculoplasty for Glaucoma
Bronx, New YorkThe goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Advanced POAG, Other Glaucoma, Others
Must Not Be Taking:Topical IOP-lowering
790 Participants Needed
Excimer Laser Trabeculostomy for Glaucoma
South Orange, New JerseyThis trial evaluates the safety and effectiveness of the ELIOS System, a procedure to lower eye pressure, in adults with mild to moderate primary open-angle glaucoma who are undergoing cataract surgery.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:45+
Sex:All
318 Participants Needed
Streamline Surgical System vs iStent for Open-Angle Glaucoma
Bronx, New YorkA study of the Streamline Surgical System versus competitor
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22+
Sex:All
150 Participants Needed
NCX 470 for Glaucoma
Bronx, New YorkThis trial is testing NCX 470 eye drops to see if they can safely and effectively lower eye pressure in people with high eye pressure or glaucoma. The goal is to protect their vision by reducing the pressure inside their eyes. NCX 470 is a nitric oxide (NO)-donating bimatoprost with clinically demonstrated pressure-lowering effects.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 84
Sex:All
696 Participants Needed
Travoprost Implant for Glaucoma
Dover, New JerseyThis trial tests a small device that releases medication inside the eye to help patients with high eye pressure due to glaucoma or ocular hypertension. The medication helps fluid drain from the eye, reducing pressure and preventing vision problems.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
105 Participants Needed
Stem Cell Therapy for Retinal and Optic Nerve Disorders
Westport, ConnecticutThis trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Inadequate Exam, No Follow-up, No Consent, Others
500 Participants Needed
Chlorhexidine Irrigation for Bladder Cancer
New York, New YorkThis is a single arm, interventional pilot study of using chlorhexidine irrigation intra-operatively and post-operatively among patients undergoing radical cystectomy with urinary diversion. The intervention comprises of using irrigation of ileal conduit or ileal neobladder intra-operatively and then for irrigation of either post-surgery with Irrisept ®. The sterilization of urine will be assessed at 10 days after cystectomy. Incidence of symptomatic urinary tract infections within the 30-day post-operative period will be estimated.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Illness, Others
40 Participants Needed
Page 1 of 1+
Frequently Asked Questions
How much do Glaucoma clinical trials in New York, NY pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Glaucoma clinical trials in New York, NY work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Glaucoma trials in New York, NY 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in New York, NY for Glaucoma is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in New York, NY several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Glaucoma medical study in New York, NY ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Glaucoma clinical trials in New York, NY ?
Most recently, we added System-Level Intervention for Visual Impairment, Patient Navigator Intervention for Vision Impairment or Blindness and Chlorhexidine Irrigation for Bladder Cancer to the Power online platform.